<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746860</url>
  </required_header>
  <id_info>
    <org_study_id>NI-MT-05</org_study_id>
    <secondary_id>ID-RCB:2017-A02668-45</secondary_id>
    <nct_id>NCT03746860</nct_id>
  </id_info>
  <brief_title>N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France</brief_title>
  <acronym>CARIOCA</acronym>
  <official_title>Non-interventional Study on the Safety and Use of Allergy Immunotherapy ACARIZAX® 12 SQ-HDM in Real-life Clinical Practice in Adult Patients With House Dust Mite Allergy in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ITEC Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional study to investigate the safety and tolerability of allergy immunotherapy
      ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (&gt;18 years) with house
      dust mite allergy over a period of 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Condition:

        -  persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving
           medication

        -  HDM allergic asthma not well controlled by inhaled corticosteroids and associated with
           mild to severe HDM allergic rhinitis. Patients' asthma status should be carefully
           evaluated before the initiation of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety analysis: Number of patients with at least one Adverse Event</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with at least one Adverse Events related to ACARIZAX®.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Allergic Rhinitis Due to House Dust Mite</condition>
  <condition>Allergic Asthma Due to Dermatophagoides Farinae</condition>
  <condition>Allergic Asthma Due to Dermatophagoides Pteronyssinus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tablet, Dispersible</intervention_name>
    <description>1 tablet/day with 12 SQ-HDM per lyo-tablet</description>
    <other_name>ACARIZAX 12 SQ-HDM</other_name>
    <other_name>Standardised allergen extract from house dust mite</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults suffering of HDM allergic rhinitis or HDM allergic asthma not well controlled by
        inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis.

        Patients are only included in the study after the decision for treatment with ACARIZAX® has
        already been made, and only with the objective of documenting data that reflects the
        treatment and its safety under 'real life' conditions. Accordingly, only examinations and
        inquiries conforming to routine practice are conducted and documented.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At the discretion of the investigator, patient who will be prescribed ACARIZAX® in
             line with the approved Summary of Product Characteristics (SmPC) and who have been
             informed, after explicit written explanation and willing to participate in the study
             by signed consent

        Exclusion Criteria:

          -  Patient who did not have 12 months prior inclusion or have an on-going, House Dust
             Mite (HDM) Allergy Immunotherapy (AIT).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal DEMOLY, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Arnaud de Villeneuve - 34090 Montpellier - FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine CHARTIER, Dr</last_name>
    <phone>+ 33 (0)1 41 02 86 51</phone>
    <email>Antoine.Chartier@alk.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie ROCHEREAU</last_name>
    <phone>33 (0)1 41 02 86 74</phone>
    <email>Marie.Rochereau@alk.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Demoly, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Davide CAIMMI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc BOURRAIN, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>Allergic Asthma</keyword>
  <keyword>House Dust Mite</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

